Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Ranbaxy Laboratories Ltd, was a listed public company incorporated on 16 June, 1961. It is classified as a public limited company and is located in , Punjab. It's authorized share capital was INR 300.00 cr and the total paid-up capital was INR 212.83 cr.
The current status of Ranbaxy Laboratories Ltd is - Amalgamated.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Rajesh Viren Shah | 00021752 | 17 years |
Kmp | Sushil Kumar Patawari | <HIDDEN> | 30 years |
Director | Arun Sawhney | 01929668 | 14 years |
Director | Percy Keku Shroff | 02143003 | 16 years |
Director | Takashi Shoda | 02436813 | 17 years |
Director | Akihiro Watanabe | 02439360 | 17 years |
Director | Tsutomu Une | 02439401 | 17 years |
Director | Anthony Hugh Wild | 02454431 | 17 years |
Director | Kazunori Hirokawa | 03562763 | 13 years |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Networth | |||||
Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
As per information available, the company has no registered charges.
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
Ranbaxy Pharmaceuticals Ukraine LLC | Ukraine | - | - |
Ranbaxy Australia Pty. Ltd. | Australia | - | - |
Ranbaxy-PRP (Peru) S.A.C. | Peru | - | - |
Office Pharmaceutique Industrial Et | France | - | - |
Be-Tabs Pharmaceuticals (Proprietary) Ltd. | South Africa | - | - |
Ranbaxy Italia S.p.A Italy | Italy | - | - |
Ranbaxy Pharma AB Sweden | Sweden | - | - |
Ranbaxy Unichem Company Ltd. Thailand | Thailand | - | - |
Ranbaxy GmbH | Germany | - | - |
Ranbaxy Nigeria Ltd | Nigeria | - | - |
Ranbaxy USA, Inc. | United States | - | - |
Basics GmbH Germany | Germany | - | - |
Ranbaxy, Inc, | United States | - | - |
GUFIC PHARMA LIMITED | Gujarat | 1983 | ₹ 5.0 L |
Ranbaxy Belgium N.V. Belgium | Belgium | - | - |
REXCEL PHARMACEUTICALS LIMITED | Delhi | 1997 | ₹ 12.5 Cr |
VIDYUT INVESTMENTS LIMITED | Punjab | 1988 | ₹ 25.0 Cr |
Ranbaxy (S.A.) (Proprietory) | South Africa | - | - |
Terapia Distributie SRL @ Romania | Romania | - | - |
Rexcel Egypt (L.L.C.) | Egypt | - | - |
SOLUS PHARMACEUTICALS LIMITED | Delhi | 1995 | ₹ 14.9 Cr |
Terapia S.A. Romania | Romania | - | - |
Ranbaxy (U.K.) Ltd. | United Kingdom | - | - |
Ranbaxy Holdings (U.K.) Ltd | United Kingdom | - | - |
Ranbaxy Malaysia Sdn. Bhd. | Malaysia | - | - |
Laboratorios Ranbaxy, S.L. Spain | Spain | - | - |
RANBAXY SEZ LIMITED | Punjab | 2008 | ₹ 5.0 L |
Ranbaxy (Hong Kong) Limited | Hong Kong | - | - |
Ranbaxy Ireland Ltd | Ireland | - | - |
RANBAXY LIFE SCIENCES RESEARCH LIMITED | Punjab | 2006 | ₹ 5.1 Cr |
Ranbaxy Poland S.P. Z.o.o. | Poland | - | - |
Sonke Pharmaceuticals (Pty) Ltd | South Africa | - | - |
Ranbaxy Pharmaceuticals Canada Inc. | Canada | - | - |
RANBAXY DRUGS AND CHEMICALS COMPANY | Delhi | 1995 | ₹ 6.2 Cr |
Ranbaxy Egypt (L.L.C.) | Egypt | - | - |
Ranbaxy (S.A | Russian Federation | - | - |
Ranbaxy Farmaceutica Ltda. Brazil | Brazil | - | - |
Be-Tabs Investments (Proprietary)Ltd. | South Africa | - | - |
Ranbaxy Pharmacie Generiques SAS | France | - | - |
Ranbaxy Signature LLC | United States | - | - |
RANBAXY DRUGS LIMITED | India | - | - |
Ranbaxy Do Brazil Ltd | Brazil | - | - |
Ranbaxy Portugal - Com E Desenvolv De Prod Farmaceuticos Unipessoal Lda Portugal | Portugal | - | - |
Ranbaxy Pharmaceutical, Inc. | United States | - | - |
Ranbaxy (Netherlands) B.V.(“RNBV”) | Netherlands | - | - |
Ranbaxy Europe Ltd. | United Kingdom | - | - |
Ohm Laboratories Inc. | United States | - | - |
Ranbaxy Morocco LLC | Morocco | - | - |
Ranbaxy Laboratories Inc. | United States | - | - |
Read more
The incorporation date of RANBAXY LABORATORIES LTD is 16 June, 1961
The authorized share capital of RANBAXY LABORATORIES LTD is INR ₹ 300.0 Cr.
The paid-up capital of RANBAXY LABORATORIES LTD is INR ₹ 212.8 Cr.
The registered address of RANBAXY LABORATORIES LTD is A-41 Industrial Area Phase VIII-A SAS Nagar Punjab - 160071
The CIN number of RANBAXY LABORATORIES LTD is L24231PB1961PLC003747.